Tripodi Armando
IRCCS Ca' Granda Ospedale Maggiore Foundation, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Via Pace 9, 20122 Milano, Italy.
Fondazione Luigi Villa, 20122 Milano, Italy.
Biomedicines. 2021 Jul 20;9(7):844. doi: 10.3390/biomedicines9070844.
Lupus anticoagulant (LA) is one of the three laboratory parameters (the others being antibodies to either cardiolipin or β2-glycoprotein I) which defines the rare but potentially devastating condition known as antiphospholipid syndrome (APS). Testing for LA is a challenging task for the clinical laboratory because specific tests for its detection are not available. However, proper LA detection is paramount for patients' management, as its persistent positivity in the presence of (previous or current) thrombotic events, candidate for long term anticoagulation. Guidelines for LA detection have been established and updated over the last two decades. Implementation of these guidelines across laboratories and participation to external quality assessment schemes are required to help standardize the diagnostic procedures and help clinicians for appropriate management of APS. This article aims to review the current state of the art and the challenges that clinical laboratories incur in the detection of LA.
狼疮抗凝物（LA）是定义罕见但可能具有毁灭性的抗磷脂综合征（APS）的三个实验室指标之一（另外两个是抗心磷脂抗体或抗β2糖蛋白I抗体）。对临床实验室而言，检测LA是一项具有挑战性的任务，因为尚无用于检测它的特异性试验。然而，准确检测LA对患者的管理至关重要，因为在（既往或当前）血栓形成事件存在的情况下其持续呈阳性是长期抗凝治疗的指征。在过去二十年中，LA检测指南已经制定并不断更新。需要在各实验室实施这些指南并参与外部质量评估计划，以帮助规范诊断程序，并协助临床医生对APS进行恰当管理。本文旨在综述LA检测的当前技术水平以及临床实验室在LA检测中面临的挑战。
